New RSV vaccines can be powerful tools, but rollout poses test

New vaccines for respiratory syncytial virus offer a significant opportunity this fall for protection against a pervasive public health threat.

Their arrival in the U.S., alongside a new antibody drug, gives public health officials and physicians powerful new tools to combat respiratory syncytial virus, or RSV, which causes thousands of deaths among young children and older adults each year.